We investigated the role of TP53 in epithelial ovarian cancer response to cisplatin, sodium arsenite (20 μM) and hyperthermia (39 °C) in wild-type TP53 expressing (A2780, A2780/CP70, OVCA 420, OVCA 429, and OVCA 433), TP53-null (SKOV-3) and TP53-mutant (OVCA 432 and OVCAR-3) ovarian cancer cells [60]. This evidence concerns the gene TP53 and ovarian cancer.